Boston Scientific’s Electrophysiology sales in Q2 2025 surged 91% thanks to Farapulse PFA and WATCHMAN FLX adoption, while Hologic’s Breast Health division is guided by new commercial leadership and innovation strategies. Both companies have successfully reduced tariff headwinds, easing operational pressures. Hologic focuses on women’s health and early detection, with a market cap of $14.94 billion, while Boston Scientific, valued at $155.90 billion, offers medical devices for a wide range of interventional medical specialties. Boston Scientific’s Cardiovascular segment excelled in the second quarter, with strong growth in Electrophysiology sales and strategic acquisitions driving momentum. Urology sales also saw significant growth, with positive projections for Neuromodulation. HOLX shares have dropped 5.4% year to date, while BSX shares have gained 18.8%. Hologic and Boston Scientific are both making progress in mitigating tariffs and expanding their product portfolios, but Boston Scientific currently appears to have the edge in terms of momentum and growth prospects.

Read more at Zacks Investment Research: HOLX vs. BSX: Which Healthcare Stock Has More Room to Grow? – August 25, 2025